MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$75,843K
EPS
-$12.31
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
5,461
6,845
13,428*
8,083
Acquired in-process research and development
59,000
-
-
-
General and administrative
16,626
4,267
5,113*
3,281
Gain on orphai acquisition
1,305
-
-
-
Goodwill impairment charge
-
-
0*
0
Intangible asset impairment charge
0
67,808
-
-
Fair value adjustment for contingent consideration
0
-64,330
3,742*
2,066
Total operating expenses
79,782
14,590
22,282
13,430
Loss from operations
-79,782
-14,590
-22,282*
-13,430
Fair value adjustment for debt
0
-12,168
396*
549
Fair value adjustment for warrants
-4,507
-31,116
15,282*
-291
Warrant issuance costs
874
-
-457*
42
Interest income
584
160
328*
300
Other (expense) income, net
152
1,719
617*
-58
Net loss before income tax expense
-75,413
30,573
-36,559*
-13,488
Income tax benefit (expense)
75
-5,339
3,183*
-46
Net income (loss)
-75,488
35,912
-39,742*
-13,442
Foreign currency translation adjustments
-355
-1,135
-662*
125
Unrealized loss on available-for-sale securities
0
-5
-56*
12
Total comprehensive loss
-75,843
34,772
-40,461
-13,305
Basic EPS
-12.31
3.6
-0.815
-0.25
Diluted EPS
-12.31
2.88
-0.815
-0.25
Basic Average Shares
6,132,845
9,120,267
49,653,081
53,951,371
Diluted Average Shares
6,132,845
9,190,354
49,653,081
53,951,371
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$75,843K
(-540.03%↓ Y/Y)
Net income (loss)
-$75,488K
(-370.36%↓ Y/Y)
Foreign currency
translation adjustments
-$355K
(-108.42%↓ Y/Y)
Net loss before
income tax expense
-$75,413K
(-371.86%↓ Y/Y)
Income tax benefit
(expense)
$75K
(11.94%↑ Y/Y)
Fair value
adjustment for warrants
-$4,507K
(-200.96%↓ Y/Y)
Interest income
$584K
(87.78%↑ Y/Y)
Other (expense)
income, net
$152K
(624.14%↑ Y/Y)
Loss from operations
-$79,782K
(-665.15%↓ Y/Y)
Warrant issuance costs
$874K
(0.23%↑ Y/Y)
Total operating
expenses
$79,782K
(665.15%↑ Y/Y)
Gain on orphai
acquisition
$1,305K
Acquired in-process
research and development
$59,000K
General and
administrative
$16,626K
(397.49%↑ Y/Y)
Research and development
$5,461K
(-16.66%↓ Y/Y)
Buy us a coffee
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)